Efficacy and Safety of Low-Dose Interleukin 2 for Primary Sjögren Syndrome: A Randomized Clinical Trial

Jing He, Jiali Chen, Miao Miao, Ruijun Zhang, Gong Cheng, Yifan Wang, Ruiling Feng, Bo Huang, Huijie Luan, Yuan Jia, Yuebo Jin, Xiaoying Zhang, Miao Shao, Yu Wang, Xia Zhang, Jing Li, Xiaozhen Zhao, Han Wang, Tian Liu, Xian Xiao, Xuewu Zhang, Yin Su, Rong Mu, Hua Ye, Ru Li, Xu Liu, Yanying Liu, Chun Li, Huixin Liu, Fanlei Hu, Jianping Guo, Wanli Liu, Wen-Bin Zhang, Alexander Jacob, Julian L Ambrus Jr, Changhai Ding, Di Yu, Xiaolin Sun, Zhanguo Li, Jing He, Jiali Chen, Miao Miao, Ruijun Zhang, Gong Cheng, Yifan Wang, Ruiling Feng, Bo Huang, Huijie Luan, Yuan Jia, Yuebo Jin, Xiaoying Zhang, Miao Shao, Yu Wang, Xia Zhang, Jing Li, Xiaozhen Zhao, Han Wang, Tian Liu, Xian Xiao, Xuewu Zhang, Yin Su, Rong Mu, Hua Ye, Ru Li, Xu Liu, Yanying Liu, Chun Li, Huixin Liu, Fanlei Hu, Jianping Guo, Wanli Liu, Wen-Bin Zhang, Alexander Jacob, Julian L Ambrus Jr, Changhai Ding, Di Yu, Xiaolin Sun, Zhanguo Li

Abstract

Importance: Primary Sjögren syndrome (pSS) is a systemic autoimmune disease associated with dysregulated immune cells, with no efficient therapy. There is a need to study potential therapeutic approaches.

Objective: To investigate the efficacy, safety, and immune response of low-dose interleukin 2 (LD-IL-2) in the treatment of pSS.

Design, setting, and participants: A double-blind, placebo-controlled randomized clinical trial was conducted with a 2-group superiority design from June 2015 to August 2017. Sixty patients, aged 18 to 70 years, were recruited from Peking University People's Hospital. Efficacy analyses were based on the intention-to-treat (ITT) principle. Data were analyzed from December 2018 to March 2020.

Interventions: Patients with pSS were treated with LD-IL-2 or placebo for 12 weeks and accompanied by 12 weeks of follow-up.

Main outcomes and measures: The primary end point was defined as a 3-point or greater improvement on the European League Against Rheumatism Sjögren's Syndrome Disease Activity Index (ESSDAI) by week 24. The secondary end points included other clinical responses, safety, and changes of immune cell subsets at week 12 and 24.

Results: Sixty patients with pSS were recruited, with 30 in the LD-IL-2 group (mean [SD] age, 47.6 [12.8] years; 30 [100%] women) and 30 in the placebo group (mean [SD] age, 51.0 [11.9] years; 30 [100%] women), and 57 completed the trial. More patients in the LD-IL-2 group (20 [66.7%]) achieved ESSDAI score reduction of at least 3 points than in the placebo group (8 [26.7%]) at week 24 (P = .004). There were greater resolutions of dryness, pain, and fatigue in the LD-IL-2 group than placebo group at week 12 (dryness: difference, -18.33 points; 95% CI, -28.46 to -8.21 points; P = .001; pain: difference, -10.33 points; 95% CI, -19.38 to -1.29 points; P = .03; fatigue: difference, -11.67 points; 95% CI, -20.65 to -2.68 points; P = .01). No severe adverse events were observed in either group. In addition, the LD-IL-2 group showed a significant decrease in infection compared with the placebo group (1 [3.3%] vs 9 [30.0%]; P = .006). Immunological analysis revealed that LD-IL-2 promoted an expansion of regulatory T cells and regulatory CD24highCD27+ B cells.

Conclusions and relevance: In this randomized clinical trial, LD-IL-2 was effective and well tolerated in patients with pSS, and it restored immune balance, with enhanced regulatory T cells and CD24highCD27+ B cells.

Trial registration: ClinicalTrials.gov Identifier: NCT02464319.

Conflict of interest statement

Conflict of Interest Disclosures: None reported.

Figures

Figure 1.. Study Flowchart and Treatment Design
Figure 1.. Study Flowchart and Treatment Design
Flowchart shows recruitment, randomization, and study population. ITT indicates intention to treat; LD-IL-2, low-dose interleukin 2.
Figure 2.. Clinical Responses to Low-Dose Interleukin…
Figure 2.. Clinical Responses to Low-Dose Interleukin 2 (LD-IL-2) Therapy
Dots indicate least square means and whiskers indicate 95% CIs after adjustment for baseline characteristics in both groups. For continuous variables, treatment differences across time points were evaluated using a mixed model and a generalized estimating equations regression analysis for repeated-measures analysis; visit, treatment group, and treatment-by-visit interactions were included in the model. ESSDAI indicates European League Against Rheumatism Sjögren’s Syndrome Disease Activity Index; STAR, Sjögren’s Tool for Assessing Response; and VAS, visual analogue scale.
Figure 3.. Immunological Responses to Low-Dose Interleukin…
Figure 3.. Immunological Responses to Low-Dose Interleukin 2 (LD-IL-2) Therapy

References

    1. Mariette X, Criswell LA. Primary Sjögren’s syndrome. N Engl J Med. 2018;378(10):931-939. doi:10.1056/NEJMcp1702514
    1. Willeke P, Schlüter B, Becker H, Schotte H, Domschke W, Gaubitz M. Mycophenolate sodium treatment in patients with primary Sjögren syndrome: a pilot trial. Arthritis Res Ther. 2007;9(6):R115. doi:10.1186/ar2322
    1. Kedor C, Zernicke J, Hagemann A, et al. . A phase II investigator-initiated pilot study with low-dose cyclosporine A for the treatment of articular involvement in primary Sjögren’s syndrome. Clin Rheumatol. 2016;35(9):2203-2210. doi:10.1007/s10067-016-3360-4
    1. Klatzmann D, Abbas AK. The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases. Nat Rev Immunol. 2015;15(5):283-294. doi:10.1038/nri3823
    1. He J, Zhang X, Wei Y, et al. . Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus. Nat Med. 2016;22(9):991-993. doi:10.1038/nm.4148
    1. James K, Chipeta C, Parker A, et al. ; UK Primary Sjögren’s Syndrome Registry . B-cell activity markers are associated with different disease activity domains in primary Sjögren’s syndrome. Rheumatology (Oxford). 2018;57(7):1222-1227. doi:10.1093/rheumatology/key063
    1. Nocturne G, Virone A, Ng WF, et al. . Rheumatoid factor and disease activity are independent predictors of lymphoma in primary Sjögren’s syndrome. Arthritis Rheumatol. 2016;68(4):977-985. doi:10.1002/art.39518
    1. He J, Tsai LM, Leong YA, et al. . Circulating precursor CCR7(lo)PD-1(hi) CXCR5+ CD4+ T cells indicate Tfh cell activity and promote antibody responses upon antigen reexposure. Immunity. 2013;39(4):770-781. doi:10.1016/j.immuni.2013.09.007
    1. Fonseca VR, Romão VC, Agua-Doce A, et al. . The ratio of blood T follicular regulatory cells to T follicular helper cells marks ectopic lymphoid structure formation while activated follicular helper T cells indicate disease activity in primary Sjögren’s syndrome. Arthritis Rheumatol. 2018;70(5):774-784. doi:10.1002/art.40424
    1. Rivière E, Pascaud J, Virone A, et al. . Interleukin-7/interferon axis drives T cell and salivary gland epithelial cell interactions in Sjögren’s syndrome. Arthritis Rheumatol. 2021;73(4):631-640. doi:10.1002/art.41558
    1. Miao M, Hao Z, Guo Y, et al. . Short-term and low-dose IL-2 therapy restores the Th17/Treg balance in the peripheral blood of patients with primary Sjögren’s syndrome. Ann Rheum Dis. 2018;77(12):1838-1840. doi:10.1136/annrheumdis-2018-213036
    1. World Medical Association . World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191-2194. doi:10.1001/jama.2013.281053
    1. Vitali C, Bombardieri S, Jonsson R, et al. ; European Study Group on Classification Criteria for Sjögren’s Syndrome . Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61(6):554-558. doi:10.1136/ard.61.6.554
    1. Seror R, Ravaud P, Bowman SJ, et al. ; EULAR Sjögren’s Task Force . EULAR Sjogren’s syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren’s syndrome. Ann Rheum Dis. 2010;69(6):1103-1109. doi:10.1136/ard.2009.110619
    1. Seror R, Ravaud P, Mariette X, et al. ; EULAR Sjögren’s Task Force . EULAR Sjogren’s Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren’s syndrome. Ann Rheum Dis. 2011;70(6):968-972. doi:10.1136/ard.2010.143743
    1. Seror R, Bootsma H, Saraux A, et al. ; EULAR Sjögren’s Task Force . Defining disease activity states and clinically meaningful improvement in primary Sjögren’s syndrome with EULAR Primary Sjögren’s Syndrome Disease Activity (ESSDAI) and Patient-Reported Indexes (ESSPRI). Ann Rheum Dis. 2016;75(2):382-389. doi:10.1136/annrheumdis-2014-206008
    1. Seror R, Baron G, Camus M, et al. ; NECESSITY WP5 - STAR development working group; NECESSITY WP5- STAR development working group . Development and preliminary validation of the Sjögren’s Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sjögren’s syndrome. Ann Rheum Dis. 2022;81(7):979-989. doi:10.1136/annrheumdis-2021-222054
    1. Iwata Y, Matsushita T, Horikawa M, et al. . Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood. 2011;117(2):530-541. doi:10.1182/blood-2010-07-294249
    1. Quick start guide. HyLown. Accessed October 4, 2022.
    1. Gao H, Zhang XW, He J, et al. . Prevalence, risk factors, and prognosis of interstitial lung disease in a large cohort of Chinese primary Sjögren syndrome patients: a case-control study. Medicine (Baltimore). 2018;97(24):e11003. doi:10.1097/MD.0000000000011003
    1. He J, Zhang R, Shao M, et al. . Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2020;79(1):141-149. doi:10.1136/annrheumdis-2019-215396
    1. Hartemann A, Bensimon G, Payan CA, et al. . Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2013;1(4):295-305. doi:10.1016/S2213-8587(13)70113-X
    1. Saadoun D, Rosenzwajg M, Joly F, et al. . Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med. 2011;365(22):2067-2077. doi:10.1056/NEJMoa1105143
    1. Koreth J, Matsuoka K, Kim HT, et al. . Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med. 2011;365(22):2055-2066. doi:10.1056/NEJMoa1108188
    1. Rosenzwajg M, Lorenzon R, Cacoub P, et al. . Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial. Ann Rheum Dis. 2019;78(2):209-217. doi:10.1136/annrheumdis-2018-214229
    1. Kolios AGA, Tsokos GC, Klatzmann D. Interleukin-2 and regulatory T cells in rheumatic diseases. Nat Rev Rheumatol. 2021;17(12):749-766. doi:10.1038/s41584-021-00707-x
    1. Arumugam P, Carroll KL, Berceli SA, Barnhill S, Wrenshall LE. Expression of a functional IL-2 receptor in vascular smooth muscle cells. J Immunol. 2019;202(3):694-703. doi:10.4049/jimmunol.1701151
    1. Krieg C, Létourneau S, Pantaleo G, Boyman O. Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells. Proc Natl Acad Sci U S A. 2010;107(26):11906-11911. doi:10.1073/pnas.1002569107
    1. Zhufeng Y, Xu J, Miao M, et al. . Modification of intestinal microbiota dysbiosis by low-dose interleukin-2 in dermatomyositis: a post hoc analysis from a clinical trial study. Front Cell Infect Microbiol. 2022;12:757099. doi:10.3389/fcimb.2022.757099
    1. Tchitchek N, Nguekap Tchoumba O, Pires G, et al. . Low-dose IL-2 shapes a tolerogenic gut microbiota that improves autoimmunity and gut inflammation. JCI Insight. 2022;7(17):e159406. doi:10.1172/jci.insight.159406
    1. Alunno A, Carubbi F, Bistoni O, et al. . T regulatory and T helper 17 cells in primary Sjögren’s syndrome: facts and perspectives. Mediators Inflamm. 2015;2015:243723. doi:10.1155/2015/243723
    1. Fox RI, Theofilopoulos AN, Altman A. Production of interleukin 2 (IL 2) by salivary gland lymphocytes in Sjögren’s syndrome: detection of reactive cells by using antibody directed to synthetic peptides of IL 2. J Immunol. 1985;135(5):3109-3115.
    1. Miyasaka N, Murota N, Yamaoka K, et al. . Interleukin 2 defect in the peripheral blood and the lung in patients with Sjögren’s syndrome. Clin Exp Immunol. 1986;65(3):497-505.
    1. Roescher N, Tak PP, Illei GG. Cytokines in Sjogren’s syndrome: potential therapeutic targets. Ann Rheum Dis. 2010;69(6):945-948. doi:10.1136/ard.2009.115378
    1. Soni C, Perez OA, Voss WN, et al. . Plasmacytoid dendritic cells and type I interferon promote extrafollicular B cell responses to extracellular self-DNA. Immunity. 2020;52(6):1022-1038.e7. doi:10.1016/j.immuni.2020.04.015
    1. Liang K, He J, Wei Y, et al. . Sustained low-dose interleukin-2 therapy alleviates pathogenic humoral immunity via elevating the Tfr/Tfh ratio in lupus. Clin Transl Immunology. 2021;10(6):e1293. doi:10.1002/cti2.1293
    1. Miao M, Xiao X, Tian J, et al. . Therapeutic potential of targeting Tfr/Tfh cell balance by low-dose-IL-2 in active SLE: a post hoc analysis from a double-blind RCT study. Arthritis Res Ther. 2021;23(1):167. doi:10.1186/s13075-021-02535-6
    1. Suzuki K, Setoyama Y, Yoshimoto K, Tsuzaka K, Abe T, Takeuchi T. Effect of interleukin-2 on synthesis of B cell activating factor belonging to the tumor necrosis factor family (BAFF) in human peripheral blood mononuclear cells. Cytokine. 2008;44(1):44-48. doi:10.1016/j.cyto.2008.06.005
    1. Gui L, Zeng Q, Xu Z, et al. . IL-2, IL-4, IFN-γ or TNF-α enhances BAFF-stimulated cell viability and survival by activating Erk1/2 and S6K1 pathways in neoplastic B-lymphoid cells. Cytokine. 2016;84:37-46. doi:10.1016/j.cyto.2016.05.017
    1. Price EJ, Rauz S, Tappuni AR, et al. ; British Society for Rheumatology Standards, Guideline and Audit Working Group . The British Society for Rheumatology guideline for the management of adults with primary Sjögren’s syndrome. Rheumatology (Oxford). 2017;56(10):1828. doi:10.1093/rheumatology/kex375
    1. Ng WF, Bowman SJ. Primary Sjogren’s syndrome: too dry and too tired. Rheumatology (Oxford). 2010;49(5):844-853. doi:10.1093/rheumatology/keq009
    1. Blattman JN, Grayson JM, Wherry EJ, Kaech SM, Smith KA, Ahmed R. Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo. Nat Med. 2003;9(5):540-547. doi:10.1038/nm866
    1. Zwirner NW, Domaica CI. Cytokine regulation of natural killer cell effector functions. Biofactors. 2010;36(4):274-288. doi:10.1002/biof.107
    1. Dutcher JP, Schwartzentruber DJ, Kaufman HL, et al. . High dose interleukin-2 (Aldesleukin): expert consensus on best management practices, 2014. J Immunother Cancer. 2014;2(1):26. doi:10.1186/s40425-014-0026-0

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する